Brief: Onxeo announces preclinical data for combination of AsiDNA and belinostat

Valerio Therapeutics SA

28/09/2017 07:01

Sept 28 (Reuters) - ONXEO SA  C4X.PA : 
    * ANNOUNCES COMPELLING PRECLINICAL DATA IN COMBINATION FOR 
ITS TWO INNOVATIVE COMPOUNDS, ASIDNA AND BELINOSTAT 
    * RESULTS DEMONSTRATE VERY STRONG SYNERGISTIC EFFECT 
BETWEEN ASIDNA, FIRST-IN-CLASS DNA BREAK REPAIR INHIBITOR 
(DBRI), AND HISTONE DEACETYLASE INHIBITORS (HDACI) 
    * POTENTIAL APPLICATION OF ASIDNA IN COMBINATION WITH ANY 
HDACI FULLY COVERED BY KEY WORLDWIDE PATENT APPLICATION 
    * PARTICULARLY HIGH SYNERGY FOR COMBINATION OF ITS TWO 
PROPRIETORY ASSETS, ASIDNA AND BELINOSAT 
    * HAS PLANNED AN EXTENSIVE PUBLICATION PLAN, STATING AT 
UPCOMING AACR MEETING IN APRIL 2018 
 
Source text for Eikon:  ID:nBw4vcGBSa  
Further company coverage:  C4X.PA  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))